The biosimilar to Rituxan is expected to erode market share of the mainstay cancer drug for Roche.
FDA has cleared a new biosimilar to Rituxan rituximab (Rituxan), which when it gets on the market may further erode sales of Roche's blockbuster treatment for non-Hodgkin's lymphoma (NHL) and other cancers.
Amgen recently achieved FDA approval for rituximab-arrx (Riabni) to treat non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) (Wegener's Granulomatosis), and microscopic polyangiitis (MPA).
Related: FDA clears Orgovyx, the first-of-its-kind prostate cancer treatment
The biosimilar is expected to be available in January. Sales of Roche's Rituxan reached $6.54 billion in 2019, so any competitor to Rituxan has much to gain.
Riabni’s wholesale acquisition cost (WAC) in the U.S. is nearly 24% lower than Rituxan at $716.80 per 100 mg and $3,584.00 per 500 mg single-dose vial, according to an Amgen press release.
Related: FDA fast-tracks investigational leukemia treatment
The FDA approved Celltrion's rituximab-abbs (Truxima), the first biosimilar to Rituxan, in 2018. The agency approved Pfizer's Ruxience (rituximab-pvvr) a year later.
Riabni, a CD20-directed cytolytic antibody, was proven to be highly similar to Rituxan based on a totality of evidence, which included comparative analytical, nonclinical and clinical data, with no clinically meaningful differences in safety or effectiveness, Amgen said.
Read more: FDA grants full approval for combination leukemia treatment
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
Microplastics, Diet and More: What’s Causing Early-Onset Cancer?
March 18th 2025In a February 2025 Time magazine cover story, Jamie Ducharme reports on this atypical and disquieting trend. Ducharme cites a 79% increase in early-onset cancer diagnoses and a 28% increase in cancer-related deaths in this age group from 1990 to 2019.
Read More